CompletedNCT00512070
Olanzapine, sleep, and metabolic changes in schizophrenia
About this title
Read the official source — NCT00512070Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- TacomaSee all locations and recruitment
Study information
Study start dateStarted: July 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00512070
- Official title
Show the full official title
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tacoma
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Seattle Institute for Biomedical and Clinical Research, a research institute.
Did this study involve medication?
Yes. The study involved medication, including olanzapine and melatonin.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
